Tryptamine Therapeutics Limited
TYPTF
$0.015
$0.000.00%
| 12/31/2024 | 11/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -2.75% | -- | |||
| Gross Profit | 2.75% | -- | |||
| SG&A Expenses | -2.75% | 2.33% | |||
| Depreciation & Amortization | -2.94% | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.75% | -13.33% | |||
| Operating Income | 2.75% | 13.33% | |||
| Income Before Tax | 2.75% | 27.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.75% | 32.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.75% | 32.97% | |||
| EBIT | 2.75% | 13.33% | |||
| EBITDA | 2.74% | -- | |||
| EPS Basic | 8.33% | 33.09% | |||
| Normalized Basic EPS | 0.00% | 26.92% | |||
| EPS Diluted | 8.33% | 33.09% | |||
| Normalized Diluted EPS | 0.00% | 26.92% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
